Table 2.
Pharmacological activity analysis based on a threshold Cmax,ss 0.373 ng/ml to define a proxy for placebo; modelled difference in change from baseline for the respective endpoints
| A) All patients, split by Cmax,ss 0.373 ng/ml | B) Patients receiving LMTM, 8 mg/day, split by Cmax,ss 0.373 ng/ml | |||||||||
| Difference±SEM | CI | p | Nlow-exposure | Nhigh-exposure | Difference±SEM | CI | p | Nlow-exposure | Nhigh-exposure | |
| ADAS-cog11 | –2.66±0.69 | –4.02, –1.30 | <0.0001 | 193 | 969 | –3.41±0.76 | –4.89, –1.92 | <0.0001 | 193 | 373 |
| ADCS-ADL23 | 0.54±0.94 | –1.30, 2.38 | 0.5634 | 192 | 967 | 1.22±1.01 | –0.77, 3.21 | 0.2283 | 192 | 373 |
| LVV (cm3) | –1.52±0.34 | –2.18, –0.85 | <0.0001 | 184 | 863 | –1.76±0.38 | –2.50, –1.01 | <0.0001 | 184 | 335 |
| WBV (cm3) | 3.55±1.10 | 1.48, 5.61 | 0.0008 | 180 | 859 | 4.39±1.18 | 2.07, 6.71 | 0.0002 | 180 | 332 |